실험실 자동화 시장 예측(-2030년)

Market Overview

Laboratory Automation Market is anticipated to register a CAGR of 8.15% during the forecast period. There are various variables driving the market development. The most conspicuous market impetuses incorporate the rising Research and development ventures and rising reception of laboratory automation frameworks.

Biotechnology and drug organizations are making huge interests in Research and development to meet the developing necessities of medical care. Expanding interests in Research and development exercises have encouraged an interest in laboratory automation frameworks and programming. Laboratory automation helps increment the productivity of the clinical laboratory's work process, bringing about a better yield on speculation (return for money invested) through decreased costs and expanded throughput, which further can possibly save lives.

In addition, labs are continually embracing innovation, including new gear, and programming. Laboratory automation includes using programming that mechanizes hardware and robots to work with insignificant human oversight, which further develops effectiveness and the nature of results. Automation in the laboratory can assist patients with getting better treatment more rapidly.

Market Segmentation

The Laboratory Automation Market segmentation, based on product type, includes automated workstations, robotic systems, software & informatics, and others. Automated workstation is further divided into automated liquid handling, microplate readers, automated Elisa systems, and automated nucleic acid purification systems. Software & informatics is segmented into electronic laboratory notebook, workstation/unit automation software, scientific data management system, and laboratory information management system.

Based on process, the market is classified into continuous flow and discrete processing. Discrete processing is further divided into the method, components, and workflow. The method type is further bifurcated into discrete centrifugal and random-access discrete processing.

Based on application the market is classified into clinical diagnostics, genomics solutions, proteomics solutions, drug discovery, and others. Based on end user, the Laboratory Automation Market is segmented into biotechnology & pharmaceutical companies, hospitals & diagnostic laboratories, and research & academic institutes.

Regional Insights

North America is credited to the rising interest in drug disclosure, rigid FDA guidelines, and the presence of enormous drug organizations, like Johnson and Johnson (US), Pfizer Inc. (US), F. Hoffmann-La Roche AG (Switzerland), Merck and Co., Inc. (US), and others.

Europe Laboratory Automation Market represents the second-biggest market share because of deep rooted medical services foundation in nations like Germany, France, the UK, and others, which has prompted an expansion in the reception of advanced mechanics and laboratory automation frameworks in the locale.

The Asia-Pacific laboratory automation market is supposed to develop at a huge offer from 2022 to 2030. This is because of the elements like further developing medical care framework, an ascent in the quantity of drug organizations, and a flood in mindfulness about cutting edge laboratory automation frameworks supporting the market development.

Major Players

Key Companies in the Laboratory Automation Market are Beckman Coulter, Inc. (US), QIAGEN N.V. (Germany), Thermo Fisher Scientific, Inc. (US), Agilent Technologies, Inc. (US), Tecan Trading AG (Switzerland), BioMerieux SA (France), Siemens Healthineer (Germany), PerkinElmer Inc. (US), Hamilton Company (US), and Hoffmann-La Roche Ltd (Switzerland).

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE
• 2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

• 3.1 DATA MINING
• 3.2 SECONDARY RESEARCH
• 3.3 PRIMARY RESEARCH
• 3.4 BREAKDOWN OF PRIMARY RESPONDENTS
• 3.5 FORECASTING TECHNIQUES
• 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
  • 3.6.1 BOTTOM-UP APPROACH
  • 3.6.2 TOP-DOWN APPROACH
• 3.7 DATA TRIANGULATION
• 3.8 VALIDATION

4 MARKET DYNAMICS

• 4.1 OVERVIEW
• 4.2 DRIVERS
  • 4.2.1 INCREASING INVESTMENT IN R&D ACTIVITIES
  • 4.2.2 RISING ADOPTION OF LABORATORY AUTOMATION SYSTEMS
• 4.3 RESTRAINTS
  • 4.3.1 HIGH INITIAL CAPITAL INVESTMENTS IN AUTOMATING LABORATORY INFRASTRUCTURE
• 4.4 OPPORTUNITIES
  • 4.4.1 IMPROVING HEALTHCARE INFRASTRUCTURE ACROSS EMERGING COUNTRIES

5 MARKET FACTOR ANALYSIS

• 5.1 VALUE CHAIN ANALYSIS
  • 5.1.1 ENGAGEMENT & DESIGNING
  • 5.1.2 MANUFACTURING
  • 5.1.3 DISTRIBUTION & SALES
  • 5.1.4 POST-SALES FOLLOW-UPS
• 5.2 PORTER'S FIVE FORCES MODEL
  • 5.2.1 BARGAINING POWER OF SUPPLIERS
  • 5.2.2 BARGAINING POWER OF BUYERS
  • 5.2.3 THREAT OF NEW ENTRANTS
  • 5.2.4 THREAT OF SUBSTITUTES
  • 5.2.5 INTENSITY OF RIVALRY
• 5.3 IMPACT OF COVID-19 ON THE LABORATORY AUTOMATION MARKET
  • 5.3.1 OVERVIEW
  • 5.3.2 IMPACT ON COST OF RAW MATERIALS
  • 5.3.3 IMPACT ON AVAILABILITY OF PRODUCTS
  • 5.3.4 IMPACT ON TRADE (IMPORT/EXPORT)

6 GLOBAL LABORATORY AUTOMATION MARKET, BY PRODUCT TYPE

• 6.1 OVERVIEW
• 6.2 AUTOMATED WORKSTATIONS
  • 6.2.1 AUTOMATED LIQUID HANDLING
    • 6.2.1.1 AUTOMATED INTEGRATED WORKSTATIONS
    • 6.2.1.2 PIPETTING SYSTEMS
    • 6.2.1.3 REAGENT DISPENSERS
    • 6.2.1.4 MICROPLATE WASHERS
  • 6.2.2 MICROPLATE READERS
    • 6.2.2.1 MULTI-MODE MICROPLATE READERS
    • 6.2.2.2 SINGLE-MODE MICROPLATE READERS
  • 6.2.3 AUTOMATED ELISA SYSTEMS
  • 6.2.4 AUTOMATED NUCLEIC ACID PURIFICATION SYSTEMS
• 6.3 ROBOTIC SYSTEMS
• 6.4 SOFTWARE & INFORMATICS
  • 6.4.1 ELECTRONIC LABORATORY NOTEBOOK
  • 6.4.2 WORKSTATION/UNIT AUTOMATION SOFTWARE
  • 6.4.3 SCIENTIFIC DATA MANAGEMENT SYSTEM
  • 6.4.4 LABORATORY INFORMATION MANAGEMENT SYSTEM
• 6.5 OTHERS

7 GLOBAL LABORATORY AUTOMATION MARKET, BY PROCESS

• 7.1 OVERVIEW
• 7.2 CONTINUOUS FLOW
  • 7.2.1 WORKFLOW
    • 7.2.1.1 SEQUENTIAL PROCESSING
    • 7.2.1.2 PARALLEL PROCESSING
  • 7.2.2 COMPONENTS
    • 7.2.2.1 CONSUMABLES
    • 7.2.2.2 EQUIPMENT
• 7.3 DISCRETE PROCESSING
  • 7.3.1 METHOD
    • 7.3.1.1 CENTRIFUGAL DISCRETE PROCESSING
    • 7.3.1.2 RANDOM ACCESS DISCRETE PROCESSING
  • 7.3.2 COMPONENTS
    • 7.3.2.1 CONSUMABLES
    • 7.3.2.2 EQUIPMENT
  • 7.3.3 WORKFLOW
    • 7.3.3.1 DEPENDENT ANALYSIS
    • 7.3.3.2 INDEPENDENT ANALYSIS

8 GLOBAL LABORATORY AUTOMATION MARKET, BY APPLICATION

• 8.1 OVERVIEW
• 8.2 CLINICAL DIAGNOSTICS
• 8.3 GENOMICS SOLUTIONS
• 8.4 PROTEOMICS SOLUTIONS
• 8.5 DRUG DISCOVERY
• 8.6 OTHERS

9 GLOBAL LABORATORY AUTOMATION MARKET, BY END USER

• 9.1 OVERVIEW
• 9.2 BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES
• 9.3 HOSPITALS & DIAGNOSTIC LABORATORIES
• 9.4 RESEARCH & ACADEMIC INSTITUTES

10 GLOBAL LABORATORY AUTOMATION MARKET, BY REGION

• 10.1 OVERVIEW
• 10.2 NORTH AMERICA
  • 10.2.1 US
  • 10.2.2 CANADA
  • 10.2.3 MEXICO
• 10.3 EUROPE
  • 10.3.1 GERMANY
  • 10.3.2 FRANCE
  • 10.3.3 UK
  • 10.3.4 ITALY
  • 10.3.5 SPAIN
  • 10.3.6 NETHERLANDS
  • 10.3.7 SWEDEN
  • 10.3.8 RUSSIA
  • 10.3.9 POLAND
  • 10.3.10 AUSTRIA
  • 10.3.11 REST OF EUROPE
• 10.4 ASIA-PACIFIC
  • 10.4.1 JAPAN
  • 10.4.2 CHINA
  • 10.4.3 INDIA
  • 10.4.4 AUSTRALIA
  • 10.4.5 SOUTH KOREA
  • 10.4.6 TAIWAN
  • 10.4.7 SINGAPORE
  • 10.4.8 MALAYSIA
  • 10.4.9 THAILAND
  • 10.4.10 REST OF ASIA-PACIFIC
• 10.5 LAMEA
  • 10.5.1 SOUTH AFRICA
  • 10.5.2 SAUDI ARABIA
  • 10.5.3 UNITED ARAB EMIRATES
  • 10.5.4 EGYPT
  • 10.5.5 REST OF LAMEA

11 COMPETITIVE LANDSCAPE

• 11.1 OVERVIEW
• 11.2 COMPETITIVE BENCHMARKING
• 11.3 MAJOR GROWTH STRATEGY IN THE GLOBAL LABORATORY AUTOMATION MARKET
• 11.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL LABORATORY AUTOMATION MARKET
• 11.5 KEY DEVELOPMENT ANALYSIS
• 11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 11.6.1 PRODUCT LAUNCH/ PRODUCT APPROVAL
  • 11.6.2 PARTERSHIP/AGREEMENT
  • 11.6.3 MERGER /ACQUISTION
• 11.7 FINANCIAL MATRIX
  • 11.7.1 SALES (USD MILLION),
  • 11.7.2 R&D EXPENDITURE (USD MILLION),

12 COMPANY PROFILES

• 12.1 THERMO FISHER SCIENTIFIC INC.
  • 12.1.1 COMPANY OVERVIEW
  • 12.1.2 FINANCIAL ANALYSIS
  • 12.1.3 PRODUCTS OFFERED
  • 12.1.4 KEY DEVELOPMENTS
  • 12.1.5 SWOT ANALYSIS
  • 12.1.6 KEY STRATEGIES
• 12.2 AGILENT TECHNOLOGIES INC.
  • 12.2.1 COMPANY OVERVIEW
  • 12.2.2 FINANCIAL OVERVIEW
  • 12.2.3 PRODUCTS OFFERED
  • 12.2.4 KEY DEVELOPMENTS
  • 12.2.5 SWOT ANALYSIS
  • 12.2.6 KEY STRATEGIES
• 12.3 TECAN TRADING AG
  • 12.3.1 COMPANY OVERVIEW
  • 12.3.2 FINANCIAL OVERVIEW
  • 12.3.3 PRODUCTS OFFERED
  • 12.3.4 KEY DEVELOPMENTS
  • 12.3.5 KEY STRATEGIES
• 12.4 BIOMERIEUX SA
  • 12.4.1 COMPANY OVERVIEW
  • 12.4.2 FINANCIAL OVERVIEW
  • 12.4.3 PRODUCTS OFFERED
  • 12.4.4 KEY DEVELOPMENTS
  • 12.4.5 KEY STRATEGIES
• 12.5 SIEMENS HEALTHINEER
  • 12.5.1 COMPANY OVERVIEW
  • 12.5.2 FINANCIAL OVERVIEW
  • 12.5.3 PRODUCTS OFFERED
  • 12.5.4 KEY DEVELOPMENTS
  • 12.5.5 SWOT ANALYSIS
  • 12.5.6 KEY STRATEGIES
• 12.6 BECKMAN COULTER, INC.
  • 12.6.1 COMPANY OVERVIEW
  • 12.6.2 FINANCIAL OVERVIEW
  • 12.6.3 PRODUCTS OFFERED
  • 12.6.4 KEY DEVELOPMENTS
  • 12.6.5 KEY STRATEGIES
• 12.7 QIAGEN N.V.
  • 12.7.1 COMPANY OVERVIEW
  • 12.7.2 FINANCIAL OVERVIEW
  • 12.7.3 PRODUCTS OFFERED
  • 12.7.4 KEY DEVELOPMENTS
  • 12.7.5 SWOT ANALYSIS
  • 12.7.6 KEY STRATEGIES
• 12.8 PERKINELMER INC.
  • 12.8.1 COMPANY OVERVIEWS
  • 12.8.2 FINANCIAL OVERVIEW
  • 12.8.3 PRODUCTS OFFERED
  • 12.8.4 KEY DEVELOPMENTS
  • 12.8.5 KEY STRATEGIES
• 12.9 HAMILTON COMPANY
  • 12.9.1 COMPANY OVERVIEW
  • 12.9.2 FINANCIAL OVERVIEW
  • 12.9.3 PRODUCTS OFFERED
  • 12.9.4 KEY DEVELOPMENTS
  • 12.9.5 KEY STRATEGIES
• 12.10 F. HOFFMANN-LA ROCHE LTD
  • 12.10.1 COMPANY OVERVIEW
  • 12.10.2 FINANCIAL OVERVIEW
  • 12.10.3 PRODUCTS OFFERED
  • 12.10.4 KEY DEVELOPMENTS
  • 12.10.5 SWOT ANALYSIS
  • 12.10.6 KEY STRATEGIES

13 APPENDIX

• 13.1 REFERENCES
• 13.2 RELATED REPORTS